Online citations, reference lists, and bibliographies.
← Back to Search

Pegylated Liposomal Doxorubicin, An Effective, Well-tolerated Treatment For Refractory Aggressive Fibromatosis.

A. Constantinidou, R. Jones, M. Scurr, O. Al-Muderis, I. Judson
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Aggressive fibromatosis (AF) or desmoid tumour is a monoclonal proliferation which is locally invasive but does not metastasize. If local treatment fails to control the disease, systemic treatment with anti-oestrogens, non-steroidal anti-inflammatory drugs (NSAIDs) or chemotherapy can be used. Recent reports indicate that pegylated liposomal doxorubicin (PLD) is effective. METHODS Twelve patients with AF received PLD between February 2006 and May 2009. PLD was administered intravenously (iv) at 50mg/m(2) over 1h every 4 weeks. RESULTS The female/male ratio was 11:1 and median age at presentation was 29 years (range 3-53). Objective response (PR) was achieved in 4 (36%) of 11 patients. In one case ongoing shrinkage of the tumour was observed for over 12 months and partial remission was achieved at 14 months after the completion of treatment. Seven patients achieved stable disease. One patient is currently undergoing chemotherapy. Clinical benefit in terms of pain relief, improved mobility or cosmesis was observed in 11 patients. Nine patients (75%) had no evidence of progression at the end of this follow-up period and disease control has ranged from 7 to 39 months with a median of 14 months. The most severe toxicities observed were palmar-plantar erythema (4) and mucositis (3). In 6 cases (55%) toxicity resulted in dose reduction. CONCLUSION This is the largest series of patients with AF receiving PLD reported to date. PLD as a single agent therapy has acceptable toxicity and highly promising activity in unresectable AF and may provide long-term clinical benefit in some patients.
This paper references
10.1002/cncr.11189
Combination chemotherapy for desmoid tumors
S. Okuno (2003)
10.1200/JCO.2005.04.0717
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
M. Heinrich (2006)
10.1055/S-2008-1043802
Chemotherapie bei Fibromatosen im Kindes-und Jugendalter: Erfahrungen der Cooperativen Weichteilsarkom Studie (CWS) und Italienischen Cooperativen Studiengruppe (ICG - AIEOP)
T. Pilz (1999)
Optimizing treatment of desmoids tumors
D Lev (2007)
Desmoid tumours in patients with familial adenomatous polyposis (FAP)
A Pikaar (2002)
10.1038/sj.onc.1203041
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor)
S. Tejpar (1999)
10.1159/000081337
Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin
G. Wehl (2004)
10.1200/JCO.2006.10.5015
Optimizing treatment of desmoid tumors.
D. Lev (2007)
10.1200/JCO.2005.03.6566
Desmoid tumors respond to chemotherapy: defying the dogma in oncology.
S. Patel (2006)
10.1007/BF02234783
Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors
L. Poritz (2001)
10.1002/14651858.CD005006.pub3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)
10.1055/S-2008-1043802
Chemotherapy in fibromatoses of childhood and adolescence: Experiences of the German Cooperative Soft Tissue Sarcoma Study (CWS) and the Italian Cooperative Study Group (ICG-AIEOP)
T. Pilz (2008)
10.1002/cncr.11937
High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors
A. Hansmann (2004)
10.1097/00000421-199904000-00020
Therapy of desmoid tumors and fibromatosis using vinorelbine.
A. Weiss (1999)
Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoids tumors
LS Poritz (2001)
10.1200/JCO.1998.16.9.3021
Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children.
S. Skapek (1998)
10.1200/JCO.2005.02.1923
Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis.
M. Gega (2006)
10.1002/cncr.20416
High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors
N. Sturt (2004)
[Chemotherapy in fibromatoses of childhood and adolescence: results from the Cooperative soft tissue sarcoma study (CWS) and the Italian Cooperative study group (ICG-AIEOP)].
T. Pilz (1999)
10.1002/cncr.11051
Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35
V. Shavers (2003)
10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)



This paper is referenced by
10.1148/rg.2016150153
Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists.
Marta Braschi-Amirfarzan (2016)
10.1038/SJ.BJC.6605997
Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients.
Santosh Bhandari (2011)
10.17116/ONKOLOG2019803115180
Experience with doxorubicin and dacarbazine in the treatment of unresectable extraabdominal desmoid fibromas
A. V. Yadrina (2019)
10.1007/S11864-017-0474-0
Desmoid-Type Fibromatosis: Who, When, and How to Treat
Javier Martínez Trufero (2017)
10.1007/s10637-017-0542-0
Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis
X. Liu (2017)
The Management of Desmoid Tumors: A joint global evidence-based consensus guideline approach for adult and pediatric patients
(2019)
10.1016/J.GASTROHEP.2012.12.005
Tumores desmoides intraabdominales en la poliposis adenomatosa familiar
Paula Galletto (2013)
10.1136/esmoopen-2018-000390
2018 ESMO Sarcoma and GIST Symposium: ‘take-home messages’ in soft tissue sarcoma
A. Frezza (2018)
10.1159/000486514
Assessment of Physician's Systemic Treatment Preferences for Patients with Advanced Desmoid-Type Fibromatosis: Experience-Based Medicine in the Absence of High-Level Evidence
P. Schöffski (2018)
10.1002/9783527634057.CH28
Development of PEGylated Liposomes
I. C. Henderson (2011)
OP-ANNO180096 51..67
P. G. Casali (2018)
FIBROMATOSIS AGRESIVA EXTRA ABDOMINAL DE CABEZA Y CUELLO
Juan Francisco Liuzzi (2014)
10.1007/s11912-014-0395-z
Advances in Therapy for Pediatric Sarcomas
A. Weiss (2014)
10.1038/bjc.2011.51
Reply: Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients
M. Nieuwenhuis (2011)
10.1093/annonc/mdr051
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG).
D. Garbay (2012)
10.3390/cancers3033394
Treatment of Extra — Abdominal Desmoid Tumors with Chemotherapy
C. Montgomery (2011)
10.1684/BDC.2013.1747
Les tumeurs desmoïdes en pédiatrie : état des connaissances actuelles
C. Oudot (2013)
10.1016/j.suc.2016.05.008
Management of Desmoids.
V. Grignol (2016)
10.1016/j.hoc.2013.07.008
Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options.
S. Devata (2013)
10.3889/mjms.1857-5773.2012.0262
Aggressive Fibromatosis Treatment - Imatinib Challenges
Gordana Damjanovska (2012)
10.1038/sj.bjc.6605997
Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients
M. Nieuwenhuis (2011)
10.1080/01676830.2018.1556306
Sino-orbital desmoid tumor in a pediatric patient – Case report with review of literature
M. A. Parulan (2018)
10.1007/978-3-030-51160-9_6
Current Approaches to Therapy: Soft Tissue Sarcomas Other than Rhabdomyosarcoma in Children and Adolescents
D. Orbach (2021)
10.1093/jjco/hyw081
Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive fibromatosis.
K. Park (2016)
10.1093/annonc/mdx323
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
B. Kasper (2017)
10.1097/CAD.0000000000000474
Pazopanib, a promising option for the treatment of aggressive fibromatosis
Z. Szucs (2017)
cacy of Imatinib in Aggressive Fibromatosis: Results of a se II Multicenter Sarcoma Alliance for Research
J. Kyle Wathen (2010)
10.1245/s10434-017-6082-1
Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor
V. Villalobos (2017)
10.1097/CCO.0000000000000374
Adult desmoid tumors: biology, management and ongoing trials
N. Penel (2017)
10.1016/j.clon.2017.05.005
Borderline Sarcomas and Smooth Muscle Tumours of Uncertain Malignant Potential.
S. Prewett (2017)
10.1158/1078-0432.CCR-10-3322
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
M. Gounder (2011)
10.1016/j.mayocp.2017.02.012
Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor
K. Skubitz (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar